Medicamen Biotec

MEDICAMENBIOTECH30 Apr 2024

Pharmaceuticals

₹

-3.40 (-0.58%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Medicamen Biotec

Medicamen Biotec

Pharmaceuticals

MEDICAMENBIOTECH30 Apr 2024

₹

-3.40 (-0.58%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
29-May-2023	D	We wish to inform that the Board of Directors of the Company in its meeting held today i.e. May 29, 2023, which commenced at 02.30 p.m. and concluded at 04.00 p.m., inter alia, considered and approved the Audited Standalone & Consolidated Financial Results of the Company for year ended March 31, 2023 , further details attached. Outcome of the Board Meeting held on August 08, 2023 (As Per BSE Announcement dated on 08.08.2023)	20-Sep-2023
25-May-2022	D	MBL has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2022, inter alia, has considered and approved the following: - Recommendation of Dividend: Payment of final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share for the Financial Year 2021-22.	19-Sep-2022
28-Jun-2021	D	Medicamen Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 26, 2021, inter alia, has recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re. 1/- per Equity Share for the Financial Year 2020-21.	16-Sep-2021
30-Jun-2020	D	Medicamen Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 30, 2020, inter alia, has recommended a Final Dividend @ 5% on Equity Shares of Rs. 10/- each i.e. 50 paise per Equity Share for the Financial Year 2019-20.	17-Sep-2020
01-Jun-2019	D	Medicamen Biotech Limited has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2019, inter alia, have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. 1 Rs per Equity Share for the Financial Year 2018-19.	17-Sep-2019
02-Aug-2017	D	Medicamen Biotech Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on August 02, 2017, inter alia, has declared an Interim Dividend of Rs. 1/- (10%) per equity share of Rs. 10/- each.	08-Aug-2017
12-Aug-2010	D	Medicamen Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12, 2010, inter alia, has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share), to be appropriated from the profits for the financial year ended March 31, 2010 subject to the approval of the shareholders at the ensuing annual general meeting.	21-Sep-2010
23-Mar-2024	BC	Shivalik Rasayan Limited	22-Mar-2024
23-Mar-2024	BC	Growel Remedies Ltd	22-Mar-2024
26-Mar-2024	BC	Geetika Madan W/o Mr. Rajesh Madan	22-Mar-2024
08-Mar-2024	BC	Geetika Madan W/o Rajesh Madan (Sale Dated on: 05/03/2024 to 07/03/2024)	05-Mar-2024
06-Mar-2024	BC	Geetika Madan W/o Rajesh Madan (Sale Dated on: 02/03/2024 to 04/03/2024)	02-Mar-2024

Announcement Date29-May-2023

Ex Dividend Date20-Sep-2023

Dividend(%)10

Announcement Date25-May-2022

Ex Dividend Date19-Sep-2022

Dividend(%)10

Announcement Date28-Jun-2021

Ex Dividend Date16-Sep-2021

Dividend(%)10

Announcement Date30-Jun-2020

Ex Dividend Date17-Sep-2020

Dividend(%)5

Announcement Date01-Jun-2019

Ex Dividend Date17-Sep-2019

Dividend(%)10

Announcement Date02-Aug-2017

Ex Dividend Date08-Aug-2017

Dividend(%)10

Announcement Date12-Aug-2010

Ex Dividend Date21-Sep-2010

Dividend(%)8

No Rights has been declared by MEDICAMENBIOTECH

Book Closure

Record Date	Split Date	Purpose
22-Mar-2024	-	Shivalik Rasayan Limited
22-Mar-2024	-	Growel Remedies Ltd
22-Mar-2024	-	Geetika Madan W/o Mr. Rajesh Madan
05-Mar-2024	-	Geetika Madan W/o Rajesh Madan (Sale Dated on: 05/03/2024 to 07/03/2024)
02-Mar-2024	-	Geetika Madan W/o Rajesh Madan (Sale Dated on: 02/03/2024 to 04/03/2024)

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Medicamen Biotech Ltd ₹579.60(-3.40/-0.58%)	579.60	-3.40	733.26	-17.94	51.43	3.64
Lupin Ltd ₹1,645.90(+8.45/0.52%)	1,645.90	+8.45	75,011.91	132.21	36.39	3.89
Ipca Laboratories Ltd ₹1,339.50(+5.50/0.41%)	1,339.50	+5.50	33,983.68	89.10	61.69	5.47
J B Chemicals & Pharmaceuticals Ltd ₹1,905.25(-1.40/-0.07%)	1,905.25	-1.40	29,568.49	83.20	58.37	11.01
Sanofi India Ltd ₹8,325.55(+48.05/0.58%)	8,325.55	+48.05	19,173.74	53.41	32.46	18.88
IOL Chemicals & Pharmaceuticals Ltd ₹393.70(-2.80/-0.71%)	393.70	-2.80	2,311.24	-3.87	13.46	1.46

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	44.20	42.67	40.50	37.15	34.12	33.53
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	44.20	42.67	40.50	37.15	34.12	33.53
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.83	0.55	0.38	0.35	0.63	0.52
Total Income	45.04	43.22	40.88	37.49	34.74	34.06
Total Expenditure	38.62	36.52	33.09	30.38	28.25	27.68
PBIDT	6.42	6.70	7.79	7.11	6.50	6.38
Interest	0.65	0.91	0.96	0.86	0.68	0.62
PBDT	5.77	5.80	6.83	6.26	5.81	5.76
Depreciation	1.76	1.80	1.68	1.61	1.60	1.62
Tax	0.99	1.19	1.25	1.08	0.78	0.86
Deferred Tax	0.26	-0.20	-0.51	-0.47	-0.33	-0.32
Reported Profit After Tax	2.77	3.01	4.42	4.05	3.76	3.61
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	2.77	3.01	4.42	4.05	3.76	3.61

EPS (Unit Curr.)	2.19	2.38	3.49	3.25	2.97	2.85
EPS (Adj) (Unit Curr.)	2.19	2.38	3.49	3.25	2.97	2.85
Calculated EPS (Unit Curr.)	2.19	2.38	3.49	3.20	2.97	2.85
Calculated EPS (Adj) (Unit Curr.)	2.19	2.38	3.49	3.20	2.97	2.85
Calculated EPS (Ann.) (Unit Curr.)	8.75	9.52	13.97	12.79	11.89	11.42
Calculated EPS (Adj) (Ann.) (Unit Curr.)	8.75	9.52	13.97	12.79	11.89	11.42
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	12.65	12.65	12.65	12.65	12.65	12.65
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	14.52	15.70	19.23	19.14	19.05	19.03
PBDTM(%)	13.05	13.59	16.86	16.85	17.03	17.18
PATM(%)	6.27	7.05	10.91	10.90	11.02	10.77

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	46.50	43.54	41.94	38.67	35.58	33.53
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	46.50	43.54	41.94	38.67	35.58	33.53
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.83	0.55	0.38	0.35	0.63	0.52
Total Income	47.33	44.09	42.32	39.01	36.21	34.06
Total Expenditure	41.61	38.90	34.99	32.18	29.70	27.68
PBIDT	5.72	5.19	7.33	6.84	6.51	6.37
Interest	0.65	0.91	0.96	0.86	0.68	0.62
PBDT	5.08	4.29	6.37	5.98	5.82	5.76
Depreciation	1.80	1.82	1.69	1.62	1.60	1.62
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.99	1.19	1.25	1.08	0.78	0.86
Deferred Tax	0.26	-0.21	-0.51	-0.49	-0.33	-0.32
Reported Profit After Tax	2.03	1.48	3.95	3.77	3.77	3.60
Minority Interest After NP	0.00	-0.04	-0.23	-0.12	0.01	0.00
Net Profit after Minority Interest	2.03	1.51	4.18	3.89	3.76	3.60

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	2.03	1.51	4.18	3.89	3.76	3.60

EPS (Unit Curr.)	1.60	1.17	3.12	3.03	2.98	2.85
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	12.65	12.65	12.65	12.65	12.65	12.65

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	12.30	11.92	17.48	17.69	18.30	19.00
PBDTM(%)	10.92	9.85	15.19	15.46	16.36	17.18
PATM(%)	4.37	3.40	9.42	9.75	10.60	10.74

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	12.65	12.22	12.22	12.22	11.70	11.70
Reserves Total	180.02	135.82	122.14	110.26	74.93	62.91
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	1.13	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	193.80	148.04	134.36	122.48	86.63	74.61
Secured Loans	25.71	25.80	18.82	9.97	11.63	14.39
Unsecured Loans	0.00	0.00	0.00	1.50	0.12	0.11
Total Debt	25.71	25.80	18.82	11.47	11.75	14.50
Total Liabilities	219.51	173.84	153.18	133.95	98.38	89.11
APPLICATION OF FUNDS :
Gross Block	130.12	124.26	115.66	57.74	46.58	45.78
Less : Accumulated Depreciation	37.76	31.78	26.02	24.05	22.20	20.45
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	92.36	92.48	89.64	33.69	24.38	25.33
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	40.50	14.76	0.28
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	4.08	2.06	2.06	2.06	0.00	0.07
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	45.06	27.01	5.20	16.96	15.26	14.23
Sundry Debtors	60.23	61.18	49.75	43.93	43.37	38.42
Cash and Bank	20.44	3.81	3.08	2.23	8.52	22.66
Loans and Advances	32.24	28.98	34.39	34.12	29.02	15.59
Total Current Assets	157.96	120.98	92.43	97.24	96.17	90.92
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	51.23	45.32	33.08	36.06	31.23	22.56
Provisions	4.39	5.09	4.78	5.23	5.58	4.30
Total Current Liabilities	55.62	50.41	37.86	41.29	36.81	26.86
Net Current Assets	102.35	70.57	54.57	55.96	59.35	64.06
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.87	0.50	0.00	0.25	0.00	0.23
Deferred Tax Liability	0.00	0.00	0.28	0.41	0.41	0.64
Net Deferred Tax	1.87	0.50	-0.28	-0.16	-0.41	-0.41
Total Assets	200.66	165.61	145.99	132.05	98.08	89.33
Contingent Liabilities	8.56	5.85	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	3.81	3.08	2.23	8.52	22.66
Net Cash from Operating Activities	-3.50	4.81	12.98	11.71	4.30
Net Cash Used In Investing Activities	-7.54	-8.47	-17.81	-39.35	-14.76
Net Cash Used In Financing Activities	27.67	4.39	5.68	21.36	-3.69
Net Inc./Dec In Cash And Cash Equivalents	16.63	0.73	0.85	-6.29	-14.15
Cash And Cash Equivalents At End Of The Year	20.44	3.81	3.08	2.23	8.52

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

43.21%

FII Shareholding

0.11%

DII Shareholding

0.99%

Public Shareholding

55.69%

**Promoter pledged shareholding 43.21%

About Medicamen Biotech Ltd

Medicamen Biotech Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 732.63 crores. It has reported a sales of Rs. 44.2 crores and a net profit of Rs. 2.77 crores for the quarter ended December 2018. The company management includes Rahul Bishnoi, Sanjay Bansal,Rahul Bishnoi,Ashwani Kumar Sharma,Harish Pande,S K Singh,Arun Kumar,Parul Choudhary,Sumita Dwivedi,Vimal Kumar Shrawat.,Sangeeta Bishnoi,Ravi Kumar Bansal (Medicamen Biotech Ltd) among others.

Chairman

Rahul Bishnoi

Registered office

1506 Chiranjiv Tower 43,Nehru Place,New Delhi,New Delhi,110019

FAX :91-11-26213081

Background

Incorporation Year1993

Face Value₹10

Market Lot1

How to buy Medicamen Biotec shares on nse?

To buy Medicamen Biotec shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Medicamen Biotec share price today?

The Medicamen Biotec shares price on nse is Rs.579.6 today.

What is the market cap of Medicamen Biotec shares on NSE ?

The company has a market capitalization of Rs.733.26Cr

What is the PE & PB ratio of Medicamen Biotec shares ?

PE is 51.43 and PB is 3.64

What is the 52 Week High and Low of Medicamen Biotec shares?

Medicamen Biotec stock price high: Rs.845 Medicamen Biotec stock price low: Rs.355.45